Solara Active Pharma Sciences Limited — Board Meeting, 15-05-2025: Outcome of Board Meeting

Solara Active Pharma Sciences has announced a board meeting to approve the financial results for the quarter and half-year. Consolidated revenue held steady at ₹1,292 Cr, while gross margins jumped to 51.5% from 37.8%, boosted by a focus on regulated markets. EBITDA turned positive at ₹214 Cr (16.5%) versus a loss last year, driven by margin gains and cost control. Net debt fell 22% to ₹776 Cr, with more cuts expected after a rights issue. The company plans to demerge its CRAMS and polymers business, shifting ₹200 Cr debt to the new entity to boost focus and ROCE. A new company secretary was appointed, and management aims for 10-20% revenue and EBITDA growth in FY26 despite ibuprofen market pressures.